Intrinsic value of West Pharmaceutical Services - WST

Previous Close

$96.23

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$96.23

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of WST stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  7.79
  6.10
  5.99
  5.89
  5.80
  5.72
  5.65
  5.58
  5.53
  5.47
  5.43
  5.38
  5.35
  5.31
  5.28
  5.25
  5.23
  5.20
  5.18
  5.17
  5.15
  5.13
  5.12
  5.11
  5.10
  5.09
  5.08
  5.07
  5.06
  5.06
  5.05
Revenue, $m
  1,509
  1,601
  1,697
  1,797
  1,901
  2,010
  2,124
  2,242
  2,366
  2,496
  2,631
  2,773
  2,921
  3,076
  3,238
  3,408
  3,586
  3,773
  3,969
  4,174
  4,389
  4,614
  4,850
  5,098
  5,358
  5,630
  5,916
  6,216
  6,531
  6,861
  7,208
Variable operating expenses, $m
 
  601
  637
  674
  712
  752
  794
  838
  884
  931
  981
  1,023
  1,078
  1,135
  1,195
  1,258
  1,324
  1,392
  1,465
  1,540
  1,620
  1,703
  1,790
  1,881
  1,977
  2,078
  2,183
  2,294
  2,410
  2,532
  2,660
Fixed operating expenses, $m
 
  782
  802
  822
  842
  863
  885
  907
  930
  953
  977
  1,001
  1,026
  1,052
  1,078
  1,105
  1,133
  1,161
  1,190
  1,220
  1,250
  1,282
  1,314
  1,346
  1,380
  1,415
  1,450
  1,486
  1,523
  1,561
  1,600
Total operating expenses, $m
  1,312
  1,383
  1,439
  1,496
  1,554
  1,615
  1,679
  1,745
  1,814
  1,884
  1,958
  2,024
  2,104
  2,187
  2,273
  2,363
  2,457
  2,553
  2,655
  2,760
  2,870
  2,985
  3,104
  3,227
  3,357
  3,493
  3,633
  3,780
  3,933
  4,093
  4,260
Operating income, $m
  197
  218
  259
  302
  347
  394
  444
  497
  553
  611
  673
  748
  817
  889
  965
  1,045
  1,130
  1,220
  1,314
  1,414
  1,519
  1,630
  1,747
  1,870
  2,000
  2,138
  2,283
  2,436
  2,597
  2,768
  2,947
EBITDA, $m
  288
  311
  357
  406
  456
  509
  565
  624
  686
  751
  820
  892
  969
  1,049
  1,133
  1,223
  1,317
  1,416
  1,520
  1,631
  1,747
  1,869
  1,999
  2,135
  2,279
  2,431
  2,590
  2,759
  2,937
  3,124
  3,322
Interest expense (income), $m
  9
  11
  12
  14
  16
  18
  20
  22
  25
  27
  29
  32
  34
  37
  40
  43
  46
  50
  53
  57
  61
  65
  69
  73
  78
  83
  88
  93
  99
  105
  111
Earnings before tax, $m
  190
  207
  246
  287
  331
  376
  424
  475
  528
  584
  644
  716
  782
  852
  925
  1,002
  1,084
  1,170
  1,261
  1,357
  1,458
  1,565
  1,678
  1,797
  1,922
  2,055
  2,195
  2,343
  2,498
  2,663
  2,836
Tax expense, $m
  55
  56
  66
  78
  89
  102
  115
  128
  143
  158
  174
  193
  211
  230
  250
  271
  293
  316
  340
  366
  394
  423
  453
  485
  519
  555
  593
  633
  675
  719
  766
Net income, $m
  144
  151
  180
  210
  241
  275
  310
  347
  386
  427
  470
  523
  571
  622
  675
  732
  791
  854
  920
  990
  1,064
  1,142
  1,225
  1,312
  1,403
  1,500
  1,602
  1,710
  1,824
  1,944
  2,071

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  203
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,717
  1,506
  1,596
  1,690
  1,788
  1,891
  1,998
  2,109
  2,226
  2,348
  2,475
  2,608
  2,748
  2,894
  3,046
  3,206
  3,374
  3,549
  3,733
  3,926
  4,128
  4,340
  4,563
  4,796
  5,040
  5,297
  5,566
  5,848
  6,144
  6,455
  6,781
Adjusted assets (=assets-cash), $m
  1,514
  1,506
  1,596
  1,690
  1,788
  1,891
  1,998
  2,109
  2,226
  2,348
  2,475
  2,608
  2,748
  2,894
  3,046
  3,206
  3,374
  3,549
  3,733
  3,926
  4,128
  4,340
  4,563
  4,796
  5,040
  5,297
  5,566
  5,848
  6,144
  6,455
  6,781
Revenue / Adjusted assets
  0.997
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
  1.063
Average production assets, $m
  781
  799
  847
  897
  949
  1,003
  1,060
  1,119
  1,181
  1,245
  1,313
  1,384
  1,457
  1,535
  1,616
  1,701
  1,790
  1,883
  1,980
  2,083
  2,190
  2,302
  2,420
  2,544
  2,673
  2,810
  2,952
  3,102
  3,259
  3,424
  3,597
Working capital, $m
  401
  163
  173
  183
  194
  205
  217
  229
  241
  255
  268
  283
  298
  314
  330
  348
  366
  385
  405
  426
  448
  471
  495
  520
  546
  574
  603
  634
  666
  700
  735
Total debt, $m
  229
  266
  304
  344
  385
  429
  474
  521
  571
  622
  676
  733
  792
  854
  919
  986
  1,058
  1,132
  1,210
  1,292
  1,377
  1,467
  1,562
  1,660
  1,764
  1,873
  1,987
  2,106
  2,232
  2,364
  2,502
Total liabilities, $m
  599
  639
  677
  717
  758
  802
  847
  894
  944
  995
  1,049
  1,106
  1,165
  1,227
  1,292
  1,359
  1,431
  1,505
  1,583
  1,665
  1,750
  1,840
  1,935
  2,033
  2,137
  2,246
  2,360
  2,479
  2,605
  2,737
  2,875
Total equity, $m
  1,118
  868
  920
  974
  1,030
  1,089
  1,151
  1,215
  1,282
  1,352
  1,426
  1,502
  1,583
  1,667
  1,755
  1,847
  1,943
  2,044
  2,150
  2,262
  2,378
  2,500
  2,628
  2,762
  2,903
  3,051
  3,206
  3,368
  3,539
  3,718
  3,906
Total liabilities and equity, $m
  1,717
  1,507
  1,597
  1,691
  1,788
  1,891
  1,998
  2,109
  2,226
  2,347
  2,475
  2,608
  2,748
  2,894
  3,047
  3,206
  3,374
  3,549
  3,733
  3,927
  4,128
  4,340
  4,563
  4,795
  5,040
  5,297
  5,566
  5,847
  6,144
  6,455
  6,781
Debt-to-equity ratio
  0.205
  0.310
  0.330
  0.350
  0.370
  0.390
  0.410
  0.430
  0.450
  0.460
  0.470
  0.490
  0.500
  0.510
  0.520
  0.530
  0.540
  0.550
  0.560
  0.570
  0.580
  0.590
  0.590
  0.600
  0.610
  0.610
  0.620
  0.630
  0.630
  0.640
  0.640
Adjusted equity ratio
  0.604
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576
  0.576

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  144
  151
  180
  210
  241
  275
  310
  347
  386
  427
  470
  523
  571
  622
  675
  732
  791
  854
  920
  990
  1,064
  1,142
  1,225
  1,312
  1,403
  1,500
  1,602
  1,710
  1,824
  1,944
  2,071
Depreciation, amort., depletion, $m
  91
  94
  99
  104
  109
  115
  121
  127
  133
  140
  147
  144
  152
  160
  168
  177
  186
  196
  206
  217
  228
  240
  252
  265
  278
  293
  308
  323
  339
  357
  375
Funds from operations, $m
  160
  245
  278
  314
  351
  390
  431
  474
  519
  567
  617
  667
  723
  782
  844
  909
  978
  1,050
  1,127
  1,207
  1,292
  1,382
  1,477
  1,577
  1,682
  1,793
  1,910
  2,033
  2,163
  2,301
  2,445
Change in working capital, $m
  -59
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  27
  28
  29
  31
  32
  34
  35
Cash from operations, $m
  219
  241
  269
  303
  340
  379
  419
  462
  506
  554
  603
  653
  708
  766
  827
  891
  959
  1,031
  1,107
  1,186
  1,271
  1,359
  1,453
  1,551
  1,655
  1,765
  1,881
  2,003
  2,131
  2,267
  2,410
Maintenance CAPEX, $m
  0
  -78
  -83
  -88
  -93
  -99
  -104
  -110
  -117
  -123
  -130
  -137
  -144
  -152
  -160
  -168
  -177
  -186
  -196
  -206
  -217
  -228
  -240
  -252
  -265
  -278
  -293
  -308
  -323
  -339
  -357
New CAPEX, $m
  -170
  -45
  -48
  -50
  -52
  -54
  -57
  -59
  -62
  -65
  -68
  -71
  -74
  -77
  -81
  -85
  -89
  -93
  -98
  -102
  -107
  -112
  -118
  -124
  -130
  -136
  -143
  -150
  -157
  -165
  -173
Cash from investing activities, $m
  -176
  -123
  -131
  -138
  -145
  -153
  -161
  -169
  -179
  -188
  -198
  -208
  -218
  -229
  -241
  -253
  -266
  -279
  -294
  -308
  -324
  -340
  -358
  -376
  -395
  -414
  -436
  -458
  -480
  -504
  -530
Free cash flow, $m
  43
  117
  137
  165
  195
  225
  258
  292
  328
  366
  406
  445
  490
  537
  586
  638
  693
  752
  813
  878
  946
  1,019
  1,095
  1,176
  1,261
  1,350
  1,445
  1,545
  1,651
  1,763
  1,880
Issuance/(repayment) of debt, $m
  -70
  37
  38
  40
  42
  43
  45
  47
  49
  52
  54
  56
  59
  62
  65
  68
  71
  74
  78
  82
  86
  90
  94
  99
  104
  109
  114
  120
  126
  132
  138
Issuance/(repurchase) of shares, $m
  -26
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -78
  37
  38
  40
  42
  43
  45
  47
  49
  52
  54
  56
  59
  62
  65
  68
  71
  74
  78
  82
  86
  90
  94
  99
  104
  109
  114
  120
  126
  132
  138
Total cash flow (excl. dividends), $m
  -36
  154
  176
  205
  236
  269
  303
  339
  377
  418
  460
  502
  549
  598
  651
  706
  764
  826
  891
  960
  1,032
  1,109
  1,189
  1,274
  1,364
  1,459
  1,559
  1,665
  1,777
  1,894
  2,019
Retained Cash Flow (-), $m
  -94
  -50
  -52
  -54
  -56
  -59
  -62
  -64
  -67
  -70
  -73
  -77
  -80
  -84
  -88
  -92
  -97
  -101
  -106
  -111
  -116
  -122
  -128
  -134
  -141
  -148
  -155
  -163
  -171
  -179
  -188
Prev. year cash balance distribution, $m
 
  206
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  310
  124
  151
  180
  210
  242
  275
  310
  347
  387
  425
  469
  514
  563
  614
  668
  725
  785
  849
  916
  986
  1,061
  1,140
  1,224
  1,312
  1,404
  1,503
  1,606
  1,715
  1,831
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  297
  113
  131
  148
  163
  175
  186
  194
  200
  203
  202
  200
  196
  189
  180
  170
  158
  145
  131
  116
  102
  88
  75
  62
  51
  41
  32
  25
  19
  14
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

West Pharmaceutical Services, Inc. develops, manufactures, and sells packaging and delivery systems in the United States, Germany, France, Other European countries, and internationally. The company’s Packaging Systems segment offers primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials; closures and other components used in syringe; intravenous and blood collection systems; and pre-fillable syringe components. This segment also provides contract analytical laboratory services for testing and evaluating primary drug-packaging components with the contained drug formulation; and specialized testing for complete drug delivery systems. Its Delivery Systems segment offers safety and administration systems, and multi-component systems for drug containment and administration. This segment’s products include Daikyo CZ insert needle syringe systems; SmartDose electronic wearable injectors; ConfiDose auto-injectors and SelfDose self-injection systems; and sterile devices for the preparation and administration of drug products comprising MixJect transfer devices, the Mix2Vial needleless reconstitution systems, the Vial2Bag systems, and vial adapters. It also provides contract-manufacturing and assembly solutions, which include technologies, such as multi-component molding, in-mold labeling, ultrasonic welding, and clean room molding and device assembly used to manufacture customer-owned components and devices for use in surgical, diagnostic, ophthalmic, other drug delivery systems, and consumer products. The company offers its components and systems for the packaging and delivery of injectable drugs; and for the pharmaceutical, healthcare, and consumer products industries. It distribute its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

FINANCIAL RATIOS  of  West Pharmaceutical Services (WST)

Valuation Ratios
P/E Ratio 48.9
Price to Sales 4.7
Price to Book 6.3
Price to Tangible Book
Price to Cash Flow 32.1
Price to Free Cash Flow 143.6
Growth Rates
Sales Growth Rate 7.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 28.8%
Cap. Spend. - 3 Yr. Gr. Rate 1.7%
Financial Strength
Quick Ratio 102
Current Ratio 0.2
LT Debt to Equity 20.3%
Total Debt to Equity 20.5%
Interest Coverage 22
Management Effectiveness
Return On Assets 8.8%
Ret/ On Assets - 3 Yr. Avg. 7.8%
Return On Total Capital 10.8%
Ret/ On T. Cap. - 3 Yr. Avg. 9.3%
Return On Equity 13.4%
Return On Equity - 3 Yr. Avg. 12.3%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 33.2%
Gross Margin - 3 Yr. Avg. 32.4%
EBITDA Margin 19.2%
EBITDA Margin - 3 Yr. Avg. 18.1%
Operating Margin 13.1%
Oper. Margin - 3 Yr. Avg. 11.7%
Pre-Tax Margin 12.6%
Pre-Tax Margin - 3 Yr. Avg. 10.9%
Net Profit Margin 9.5%
Net Profit Margin - 3 Yr. Avg. 8.4%
Effective Tax Rate 28.9%
Eff/ Tax Rate - 3 Yr. Avg. 26.4%
Payout Ratio 25%

WST stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the WST stock intrinsic value calculation we used $1509 million for the last fiscal year's total revenue generated by West Pharmaceutical Services. The default revenue input number comes from 2016 income statement of West Pharmaceutical Services. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our WST stock valuation model: a) initial revenue growth rate of 6.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for WST is calculated based on our internal credit rating of West Pharmaceutical Services, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of West Pharmaceutical Services.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of WST stock the variable cost ratio is equal to 37.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $763 million in the base year in the intrinsic value calculation for WST stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.7% for West Pharmaceutical Services.

Corporate tax rate of 27% is the nominal tax rate for West Pharmaceutical Services. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the WST stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for WST are equal to 49.9%.

Life of production assets of 9.6 years is the average useful life of capital assets used in West Pharmaceutical Services operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for WST is equal to 10.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1024 million for West Pharmaceutical Services - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 72.122 million for West Pharmaceutical Services is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of West Pharmaceutical Services at the current share price and the inputted number of shares is $6.9 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
ATRS Antares Pharma 3.19 prem.  prem.
BDX Becton Dickins 194.91 prem.  prem.
RVP Retractable Te 1.33 prem.  prem.
PODD Insulet 50.42 prem.  prem.
ATR Aptargroup 86.93 prem.  prem.
ICUI ICU Medical 174.75 prem.  prem.
CTLT Catalent 35.79 prem.  prem.
CRL Charles River 101.20 prem.  prem.

COMPANY NEWS

▶ West Elects New Director to the Board   [Jun-01-17 08:00AM  PR Newswire]
▶ Why West Pharmaceutical Services Is Rising Today   [Apr-27-17 04:04PM  Motley Fool]
▶ West Pharmaceutical tops Street 1Q forecasts   [08:08AM  Associated Press]
▶ West Announces First-Quarter 2017 Results   [07:00AM  PR Newswire]
▶ West to Host First-Quarter 2017 Conference Call   [Apr-13-17 08:00AM  PR Newswire]
▶ West Pharmaceutical misses Street 4Q forecasts   [07:30AM  Associated Press]
▶ West to Present at J.P. Morgan Healthcare Conference   [Dec-28-16 08:00AM  PR Newswire]
▶ Hedge Funds Are Selling West Pharmaceutical Services Inc. (WST)   [Dec-08-16 05:44AM  at Insider Monkey]
▶ Do Hedge Funds Love SS&C Technologies Holdings, Inc. (SSNC)?   [Nov-26-16 07:08AM  at Insider Monkey]
▶ West Announces Third Quarter 2016 Results   [07:00AM  PR Newswire]
▶ West to Host Third Quarter 2016 Conference Call   [Oct-13-16 07:00AM  PR Newswire]
▶ West to Host Second Quarter 2016 Conference Call   [Jul-14-16 08:30AM  PR Newswire]
▶ West Announces Quarterly Dividend   [Jul-05-16 04:30PM  PR Newswire]
▶ West to Present at Investor Conference in June   [Jun-01-16 08:00AM  PR Newswire]
Stock chart of WST Financial statements of WST Annual reports of WST
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.